Trial Profile
Randomized open multicenter study to assess efficacy (for patient outcome) and safety of a single dose (i.v.) of NMK36 in patients with clinically- suspected glioma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Fluciclovine 18F (Primary)
- Indications Glioma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Nihon Medi-Physics
- 22 Dec 2017 Status changed from active, no longer recruiting to completed.
- 01 Nov 2016 Status changed from recruiting to active, no longer recruiting.
- 20 Jan 2016 New trial record